Glioblastoma Multiforme is a highly aggressive brain malignancy commonly refractory to classical and novel chemo-, radio-and immuno-therapies, with median survival times of ~15 months following diagnosis. Poor immunological responses exemplified by the downregulation of T-cell activity, and upregulation of immunosuppressive cells within the tumour micro-environment have limited the effectiveness of immunotherapy in GBM to date. Here we show that GBM cells express a large repertoire of inhibitory checkpoint ligands. Furthermore, GBM cells with an enhanced stem cell-like phenotype exhibit heightened levels of inhibitory checkpoint ligands, compared to non-stem cell-like GBM cells. Understanding how GBM modulates an extensive repertoire of immune checkpoint ligands and the functional consequence on immune evasion are necessary to develop effective immuno-therapeutics.
Background
Glioblastoma Multiforme (GBM) is classified as a WHO Grade IV astrocytoma that continues to circumvent classical and novel chemo-, radio-and immuno-therapies through extensive intratumoral heterogeneity (1, 2) . Like the surrounding central nervous system (CNS) tissue GBM tumours exhibit intrinsic complexity through the presence of interacting microglia, macrophages, astrocytes, oligodendrocytes, neurons, glial and neuronal progenitor cells, pericytes, and endothelial cells (1). In particular, the identification of a subpopulation of cells that share features reminiscent of neural stem cells was first described by Singh et al. (2004) , who demonstrated that CD133 + cells isolated from human GBM tumours were unique in their ability to self-renew and recapitulate parent tumours in mouse xenograft assays (3) . The importance of stem cell-like populations residing within GBM tumour microenvironments has been shown, with cancer stem cell populations demonstrating the propensity to initiate and maintain tumour growth, promote immune evasion, enhance intratumoral angiogenesis, and desensitise GBM to radio-and chemo-therapies (4, 5) . Clinically, the presence of GBM cancer stem cells (gCSCs) is associated with progression from low grade to high grade gliomas, in part due to vast cancer stem cell interactomes (6) . Specifically, GBM tumours actively interact with immune cell populations, potentially through multiple immune checkpoint ligand-receptor interactions.
Immune checkpoint molecules are essential cell-surface receptors utilised by immune cells to mediate intercellular communication ( Figure 1) (7) . Inhibitory checkpoint receptors serve to negatively regulate the development and effector functions of lymphocyte subsets; namely effector T-cells and natural killer cells, with activation of regulatory T -cells (Treg) also reported (7, 8) . Through the expression of ligands to checkpoint receptors tumour cells effectively suppress immune reactivity (8) . In recent years there has been a growing appreciation that a range of these inhibitory checkpoint ligands are expressed throughout the GBM microenvironment (9, 10) . Particularly, the expression of programmed death 1 (PD-1; the cognate receptor to PD-L1) in GBM tumours can be as high as 88% (11) . Cytotoxic Tlymphocyte-associated protein-4 (CTLA-4) is an additional checkpoint receptor frequently upregulated by T cells within GBM (12) . The presence of PD-1 and CTLA-4 is clinically associated with reduced immunological elimination of malignant cells, primarily through either an increase in T-cell anergy or enhanced Treg mediated immunosuppression. FDA approved therapies (originally for melanoma; ipilimumab, pembrolizumab and nivolumab) aimed at disrupting these inhibitory checkpoint signals are in clinical trials for the treatment of GBM (13) .
In addition to PD-1 and CTLA-4, other immune checkpoints have been described in GBM, with minimal understanding of their functional relevance (14) . An important consideration in the investigation of immune-suppression is the expression and modulation of checkpoint ligands by glioma cancer stem cells. Emerging studies have linked increased PD-L1 expression to CD44 + and CD133 + CSC populations in non-CNS tumours (14) . Wu et al. (2017) demonstrated that both MCF-7 breast cancer and HCT-116 colon cancer cultures enriched for cancer stem cells as defined by CD44 high CD24 low phenotypes exhibit significantly higher percentages of PD-L1 positive cells (15) . While the functional implications of elevated checkpoint ligand expression by CSC populations is still unclear, the findings reinforce the multi-faceted role CSCs may play in solid tumour immuno-modulation.
The recent FDA approvals of anti-CTLA-4 and anti-PD-1 immunotherapies have propelled the benefits of targeting immune checkpoints into the spotlight. However, as multiple checkpoint ligands have been demonstrated to play complementary roles in the inhibition of T-cell activity, monotherapies as a means of countering checkpoint mediated immune suppression may not provide the greatest anti-tumour effects (16) . For example tumours are able to escape anti-CTLA-4 monotherapy via upregulation of PD-1/PD-L1 interactions (17) . It is apparent that inhibitory checkpoint receptor signalling function in concert to mediate inappropriate immune down-regulation. Thus, understanding the extent of checkpoint ligand expression within GBM tumours is necessary to develop functional, long-lasting therapeutics. In this study, we investigate the expression of an extensive range of suppressive checkpoint ligands by two primary New Zealand glioblastoma cell lines. Additionally, we highlight the enhanced expression of checkpoint ligands by stem cell-like enriched populations and recognise the implications of cancer stem cells for future immunotherapeutic interventions.
Methods

Cell culture
Primary New Zealand Glioblastoma cell lines. NZB11 and NZB19 primary cell lines were provided in collaboration with the Auckland Cancer Society Research Centre. The cells were acquired at a low passage and routinely cultured at 37 ˚C in 5% O2, 5% CO2. Cells were cultured as adherent monolayers on uncoated 75 cm 2 culture flasks until 80-90% confluent.
For experimental conditions requiring fetal bovine serum (FBS), cells were cultured in α
Minimal Essential Medium (MEM) (ThermoFisher) supplemented with 5% FBS (Moregate) and 1x insulin-transferrin-selenium (ITS) (Sigma) (herein referred to as serum-cultures).
Adherent GBM Cancer Stem Cell-Like Cells (gCSC). Adapted from established glioma stem cell protocols (18) , adherent gCSCs were expanded for experimental use and routinely cultured at 37 ˚C in 5% O2, 5% CO2. NZB11 and NZB19 primary cell lines at low passages were transferred into 25 cm 2 culture flasks coated with 10 µg/mL laminin (ThermoFisher). NT2-Astrocytes (NT2A). NT2A cells were generated as described previously (19) and were cultured on uncoated 25 cm 2 culture flasks in DMEM/F12 at 37 ˚C in 20% O2, 5% CO2.
Imaging. For phase imaging of each respective cell culture, cells were imaged at equivalent confluences on EVOS FL auto imaging system (ThermoFisher) at either 10x or 20x magnification.
Limited Dilution Assay
As per sphere forming conditions, gCSC NZB11 and NZB19 primary cell lines were grown in gCSC culture medium in the absence of laminin coating. To determine gCSC self-renewal potential, primary GBM glioma-spheres were treated with Accutase and triturated until all cells were in single cell suspension. Single cells derived from primary spheres were then seeded into 96 well plates at a cell seeding density of 5 cells per µL. After 2 weeks the number of spheres greater than 80 µm in diameter were counted. Sphere forming efficiency (SFE) was determined by calculating (No. spheres < 80 µm / No. cells seeded)*100.
Flow Cytometry
The expression of surface stem cell-associated molecules and checkpoint ligands were determined by flow cytometry. Primary cell lines were cultured in 75 cm 2 culture flasks under respective culture conditions until 80-90% confluent. Medium was removed and cells were washed with 1x PBS (ThermoFisher). Following removal of PBS, cells were treated with Accutase (Sigma) for 5 min at room temperature until all cells were in single cell suspension.
Accutase was diluted 1:2 with warm medium and suspended cells were centrifuged for 5 min at 300 x g. The supernatant was discarded, and the cells were re-suspended in medium. For flow cytometry preparation, 100,000 cells were added to round-bottom polystyrene tubes for antibody incubations. Cells were incubated at a 1:20 dilution (5 µL into 100 µL cell suspension) for 15 min at 4 o C with conjugated primary antibody (Table 1) . 7-AAD (BioLegend) was used for live/dead discrimination. Following incubations, each tube was washed once with 2 mL FACS buffer (PBS containing 1% FBS) and centrifuged for 5 min at 300 x g at 4 ˚C.
Supernatant was decanted and cells were vortexed vigorously immediately prior to flow cytometry analysis. Cells were analysed using a BD Accuri C6 Flow Cytometer. Data was processed using FlowJo v.7.6.5 software. Dot plots were created in GraphPad Prism v.7. 
Immunocytochemistry
Cells cultured in serum and gCSC medium were seeded at 5000 cells/0.33cm 2 into either uncoated or laminin coated 96 well plates, respectively. Cells were allowed to settle and continue to proliferate for a further 48 hrs and then fixed. Cells were fixed in either 4% paraformaldehyde (PFA) or 95% methanol, 5% acetic acid for 10 min and then washed once with 1x PBS. Cells fixed in PFA were permeabilised for a further 10 min in 0.1% PBS-Triton X-100 (PBS-T). Cells were washed and stored in PBS. For immunocytochemical analysis, PBS was aspirated, and cells were blocked in 1% Bovine Serum Albumin (BSA) for 45 min and washed thrice for 10 min in 0.1% PBS-T. Primary antibodies were diluted, as per table 2, in 1% BSA and incubated with cells for 1 h at room temperature on a rocker. After primary antibody incubations, cells were washed as previously described and incubated with either 1:400 goat anti-mouse 488 conjugated secondary (Cat. #A11001) or 1:400 goat anti-rabbit 594 conjugated secondary (Cat. #A11005) made up in 1% BSA for 1 hr at room temperature. Cells were counterstained with 1:10,000 Hoechst 33342 (ThermoFisher). Cells were then washed as previously described and stored in PBS. For imaging, EVOS FL auto imaging system (ThermoFisher) was used and ImageJ was used to process images. 
Confocal Microscopy
Glioma-spheres were added to 16-well chamber slides (ThermoFisher) coated with 1:50
Matrigel. Spheres were cultured for 1 hr until they adhered loosely. Spheres were fixed in either 4% PFA or 95% methanol, 5% acetic acid for 10 min and then washed once with 1x PBS.
Spheres fixed in PFA were permeabilised for a further 10 min in 0.1% PBS-Triton X-100 (PBS-T). Spheres were washed and stored in PBS. For immunocytochemical analysis, PBS was aspirated and spheres were blocked in 1% Bovine Serum Albumin (BSA) for 45 min and washed thrice for 10 min in 0.1% PBS-T. CD44, GFAP, vimentin, nestin and BIII Tubulin primary antibodies were diluted, as indicated in Table 2 , in 1% BSA and incubated with spheres for 1 h at room temperature on a rocker. After primary antibody incubations, spheres were washed as previously described and incubated with either 1:400 goat anti-mouse 488 conjugated secondary (Cat. #A11001) or 1:400 goat anti-rabbit 594 conjugated secondary (Cat. #A11005) made up in 1% BSA for 1 hr at room temperature. Spheres were counterstained with 1:10,000 Hoechst 33342 (ThermoFisher). Spheres were then washed as previously described and stored in PBS. For imaging, an Olympus FV1000 confocal microscope was used and ImageJ was used to process images.
In silico analysis of GBM checkpoint ligand expression CD80
"CD80" OR "B7-1" OR "BB1" OR "CD28LG" OR "CD28LG1" OR "LAB7" CD86 "CD86" OR "B7-2" OR "B7.2" OR "B70" OR "CD28LG2" OR "LAB72"
PD-L1
"CD274" OR "B7-H" OR "B7H1" OR "PD-L1" OR "PDCD1L1" OR "PDL1" OR "Programmed cell death 1 ligand 1" PD-L2 "PDCD1LG2" OR "B7DC" OR "Btdc" OR "CD273" OR "PD-L2" OR "PDL2" OR "programmed cell death 1 ligand 2" OR "PDCD1" OR "CD279" CEACAM-1 "CEACAM1" OR "BPG" OR "CD66" OR "Carcinoembryonic antigen related cell adhesion molecule 1" OR "NKG2" CD155
"PVR" OR "CD155" OR "HVED" OR "NECL5" OR "PVS" OR "TAGE4" OR "poliovirus receptor" Galectin-9
"LGALS9" OR "HUAT" OR "
LGALS9A" OR "Galectin 9" OR "Galectin-9" B7-H3 "CD276" OR "4IG-B7-H3" OR "B7-H3" OR "B7H3" OR "B7RP-2" OR "CD276 molecule"
B7-H2
"B7-H2" OR "ICOSLG" OR "B7H2" OR "B7HRP-1" OR "B7HRP1" OR "CD275" OR "ICOS-L" OR "LICOS" OR "ICOS LIGAND"
H7-H4
"VTCN1" OR "B7-H4" OR "B7H4" OR "B7S1" OR "B7X" OR "PRO1291" OR "VCTN1" OR "V-set domain containing T cell activation inhibitor 1" HVEM "TNFSF14" OR "ATAR" OR "CD270" OR "HVEA" OR "HVEM" OR "LIGHTR" OR "TR2" OR "TUMOUR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 14" OR "TNF RECEPTOR SUPERFAMILY MEMBER 14" OR "BTLA" OR "CD272" OR "B and T lymphocyte associated"
Statistical Analysis
Each experiment was repeated three times with representative data shown where applicable.
For flow cytometry data, median fluorescent intensities across three independent repeats are presented with students T-tests used for statistical comparisons. GraphPad v.7 was used to generate statistical tests. P = 0.05 (*), 0.01 (**), 0.001 (***), 0.0001(****).
Results
Primary New Zealand GBM cell lines readily form adherent cells and free floating glioma-spheres in gCSC culture
To establish GBM cancer stem cell-like cells (gCSCs) in vitro, the absence of serum in combination with key mitogens such as EGF and bFGF is required (18) . To assess the ability of primary New Zealand GBM cell lines to be grown as gCSCs, NZB11 and NZB19 primary 
GBM cancer stem cell-like cells exhibit increased stem cell associated phenotypes compared to serum-exposed cells
To validate the hypothesis that the gCSC adherent cultures promote the development of cancer stem cells, both primary cell lines were assessed using flow cytometry and immunocytochemistry for the expression of key cancer stem cell associated markers and neural lineage differentiation markers. Both primary cell lines were analysed for their expression of CD133, A2B5, CD44 and CD49F by flow cytometry (Figure 3 ). All markers were detected at significant in the serumsupplemented medium. When grown as gCSCs, the expression of A2B5 significantly increased in both primary cell lines. While gCSC cultures did not express CD133 and CD49F substantially above serum-cultured cells, there is a definite increase in the overall stem celllike phenotype of both primary cell lines grown as gCSCs (Figure 3, B) . It is important to note that gCSC A2B5 expression was not only elevated, but also showed broader expression profiles according to flow cytometry histograms (Figure 3, A) .
Next, comparisons between the expression of key stem cell associated and differentiation markers were made by immunocytochemical analysis (Figure 4 ) (Figure 4, B) .
Furthermore, the expression of nestin, GFAP, CD44, vimentin and BIII Tubulin by GBM derived glioma-spheres was determined ( Figure 5 ). Z-stack analyses revealed that CD44 is expressed throughout glioma-spheres, whereas GFAP, nestin, vimentin and BIII Tubulin are localised to sphere peripheries ( Figure S3-S6 ). The expression profiles between spheres are consistent between both primary cell lines, however the varied expression within each sphere indicate that while a homogenous population of gCSCs forms spheres, the spheres themselves are inherently heterogeneous. likely expressing CD80 in two separate populations as indicated by an emerging bimodal profile ( Figure 6 ).
Next, we compared serum-supplemented and gCSC median florescence intensities of the 11 checkpoint ligands against a glial control (NT2A). NZB11 cells express PD-L1 (p=0.0068), PD-L2 (p=0.0002), CD80 (p=0.0083), CD155 (p=0.0046), B7-H2 (p=0.0313), B7-H3 (p=0.0058) and HVEM (p=0.0003) ( Figure S8 ). NZB19's show expression of PD-L1 (p=0.0277), PD-L2 (p=0.0033), CD80 (p=0.0058), CEACAM-1 (p=0.0057), CD155 (p=0.0030), Galectin-9
(p=0.0097), B7-H3 (p=0.0051) and HVEM (p=0.0264) ( Figure S8 ). The flow cytometry analysis reveals the trend that checkpoint ligands are commonly expressed at higher levels than are seen with non-transformed neural cells, with NZB11's and NZB19's positive for 63.6 % and 72.7 % of inhibitory checkpoint ligands, respectively ( Figure S8 ).
As the expression of the aforementioned ligands has been shown to be associated with worsening grade in gliomas and some cancer stem cells in non-CNS tumours, we sought to investigate the expression of these molecules by GBM gCSC cultures. Of the 11 ligands, both the NZB11 and NZB19 gCSCs showed greater levels of surface expression of 3 of the 11 ligands than that of serum-cultured cells (Figure 7) . In particular, NZB11 gCSCs expressed surface PD-L1, CD155 and B7-H3 at 23.3, 73.2 and 65.0 fold above that of serum-cultured cells, respectively (Figure 7 ). In addition, there was a slight increase (not significant) for PD-L2, CD80, Galectin-9, HVEM, and CD86 in the gCSC cultures.
Of interest was the observation that the NZB19 gCSC cultures had significantly more B7-H3, B7-H2, and HVEM, but there was no change in PD-L1 or PD-L2. Also contrary to other NZB11 gCSC changes, the surface expression of CD155 was reduced in the gCSC NZB19 cell cultures. (Figure 7) . This is very intriguing as not all ligands are elevated, and it is not the same complement of ligands changing across these two distinct lines. Clinically, very few of these molecules are currently being targeted and typically are only targeted by monotherapy. This data reinforces the urgent need to consider checkpoint ligands as a collective group that are differentially regulated and expressed across patient derived glioblastomas. 
Discussion
The resounding successes of anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) in maintaining durable response in melanoma led to the start of a range of clinical trials in GBM (16, 24) . Successful treatment of GBM has remained modest at best, with immunotherapies against immune checkpoint ligand-receptor interactions failing to translate into adequate clinical responses. At the forefront of GBM immune checkpoint inhibition was the phase 3, randomised CHECKMATE-143 trial. While the trial failed to induce enhanced overall response rates (8%) in comparison to bevacizumab; an anti-angiogenic (23%), further clinical trials arising from the original concept are underway (25) . In particular, trials utilising the combination of nivolumab with either temozolomide, radiation or ipilimumab have commenced, with results pending (26) (27) (28) . However, the benefits of immune checkpoint inhibition has been limited, primarily due to the commonly low GBM mutational burden and the frequent depletion of lymphocytes within the tumour microenvironment (29, 30) . One investigation of a small cohort Presented here is, to the best of our knowledge, the first extensive characterisation of surface expression of immune checkpoint ligands with known immune suppressive functions ( Figure   6 ). Surface expression analyses of 11 checkpoint ligands reputed to be immunosuppressive within tumour microenvironments revealed that primary New Zealand GBM cells ubiquitously express these ligands (32) . An in-silico review of glioblastoma literature revealed that all ligands have been investigated, except for HVEM (Table S1 ). However, to date investigations have been heavily skewed towards the PD-L1/PD-1 axis, with limited literature on expression profiles of PD-L2, CD80, CD86, B7-H2, B7-H3, B7-H4, CEACAM-1, HVEM and CD155 in human GBM. Collectively, an in-silico search revealed that 55% of checkpoint ligand studies in GBM were centred on PD-L1 expression. Therefore, extending our investigation beyond commonly investigated ligands was of importance. Of the ligands we have investigated here, PD-L1, CD155, PD-L2 and B7-H3 surface expression levels are between 8 to 118-fold higher on GBM cells than on astrocytic controls ( Figure S8 ). All 4 ligands are unanimously reported to be expressed in human GBM (Table S1) other study has also demonstrated this correlation, whereby high grade gliomas showed high correlations between PD-L2, CD80 and PD-L1 (35) . Collectively, this highlights the impact of checkpoint ligand expression on glioma grade and subsequent immune evasion. However, only 18% of human glioma investigations looked at expression levels of multiple ligands, and frequently only in the scope of PD-1/PD-L1/2 and CTLA-4/CD80/86 axes (Table S1 ). Clinically, expression of multiple ligands poses challenges in targeting GBM through checkpoint inhibition, as the regulation of these ligands in concert is still unclear.
To maximise the potential of immunotherapies, the mechanisms exploited by GBM to promote enhanced checkpoint ligand expression need to be understood. The intrinsic heterogeneity in not only the classification of GBM, but within the tumour microenvironment heavily influences the poor patient survival and ultimate recurrence that is observed (36) . In particular, recurrence is likely due to residual GBM subpopulations of stem cells (37) . Currently markers reputed for delineating GBM cancer stem cells within the tumour microenvironment include CD133, CD44, A2B5, CD15 and CD49F (38) . GBM cancer stem cells can be broadly classified as pro-neural, non-adherent, non-invasive CD133 + populations, or as semi-adherent, invasive mesenchymal CD44 + populations (37, 39) . Flow cytometry analysis revealed that both NZB11 and NZB19 primary cell line derived gCSCs showed increased A2B5 levels. However, NZB11 gCSCs highly expressed CD44, but did not show an increase in CD133 expression ( Figure 3 ).
Conversely, NZB19 gCSCs did not show an increase in CD44, but did exhibit elevated CD49F and a non-significant increase in CD133 (Figure 3 ). These findings exemplify that GBM stem cells display a range of phenotypic characteristics, reiterated by Brown et el. (2015) , despite retaining classic cancer stem cell features such as sphere forming ability ( Figure 2 ) (37) . To determine the role cancer stem cell populations may play in promoting immunological blockades, our two distinct gCSC lines were screened for the 11 checkpoint ligands previously described (Figure 7 ). gCSCs are known to impede immunity through multiple modalities, in particular through the expression of inhibitory checkpoint ligands and consequential T-cell anergy (40) . Elevated expression by two gCSC lines of 5 of the 11 checkpoint ligands was shown. Importantly, the distinct gCSCs did not show identical expression patterns. The differential expression levels of the checkpoint ligands indicate that phenotypically different gCSCs may utilise discrete repertoires of inhibitory molecules to mediate immune inhibition.
B7-H3, the only commonly elevated ligand by NZB11 and NZB19 gCSCs, expression correlates with glioma grade and negatively correlates with T-cell mediated immune response to glioma (41, 42) . While B7-H3 expression has not been well characterised on glioma cancer stem cell subsets beyond this study, the elevated expression here suggests to a mechanism by which B7-H3 expression on GBM cancer stem cells could drive worsening prognosis through enhanced immunological inhibition.
Conclusions
The data here indicates that an increased GBM stem cell-like phenotype results in elevated expression of a range of checkpoint ligands, beyond the extensive repertoire already expressed by serum-cultured cells. The role of checkpoint ligand expression by GBM cancer stem cell subsets ultimately warrants further investigation. Attempting to target these subsets and the mechanisms they use to actively evade immune detection provides a unique therapeutic opportunity in the context of immunotherapies against Glioblastoma Multiforme. 
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